<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
<!--    <meta content="width=device-width, initial-scale=1.0" name="viewport">-->
    <title>GA TB Reference Guide </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
    <style>
        /* Scoped styles for Table 15 */
        .table-15-container .uk-table th,
        .table-15-container .uk-table td {
            width: 50% !important;
        }

        .table-15-container .tab-button {
            width: 250px;
            height: 100px;
            white-space: normal;
            text-align: center;
            padding: 0.5rem;
            font-size: 0.9rem;
            flex: none;
        }

        .table-15-container .tabs {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            margin-bottom: 1rem;
            justify-content: center;
        }

        /* Responsive adjustments for tabs */
        @media (max-width: 959px) {
            .table-15-container .tab-button {
                width: 200px;
                height: 70px;
            }
        }
    </style>
</head>

<body>
<div class="uk-container">
    <p> <span class="view-in-chapter-highlight"> View in chapter → <span> <a href="5_treatment_of_current_(active)_disease_therapy__c__special_clinical_situations.html/#table15"> Special Clinical Situations </a></p>
    <p class="last-updated"><i>Last Updated June 2024</i></p>
    <hr>
    <div class="uk-overflow-auto table-15-container" id="table_15_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated">
        <div class="tabs">
            <button class="tab-button" onclick="switchTab(0, event)">Critical illness requiring vasopressors</button>
            <button class="tab-button" onclick="switchTab(1, event)">Proven or suspected meningeal TB</button>
            <button class="tab-button" onclick="switchTab(2, event)">Patient age 75 years or greater</button>
            <button class="tab-button" onclick="switchTab(3, event)">Disseminated TB with concern for poor absorption</button>
            <button class="tab-button" onclick="switchTab(4, event)">Patient receiving medications via nasogastric or PEG tube</button>
            <button class="tab-button" onclick="switchTab(5, event)">Baseline elevation of liver enzymes</button>
            <button class="tab-button" onclick="switchTab(6, event)">Acute hepatitis after starting standard therapy</button>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>Poor gut medication absorption</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>1-IV rifampin ≥ 10 mg/kg daily+<br>
                        2-PO pyrazinamide UD+<br>
                        3-PO ethambutol UD+<br>
                        4-IV isoniazid UD<sup>2,3</sup>+<br>
                        5-IV levofloxacin or moxifloxacin UD 4+<br>
                        6-IV linezolid UD 5<sup>4</sup>+<br>
                        7-IV amikacin UD<sup>5</sup></td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>Oral medications are generally poorly bioavailable among critically ill patients.<p>Patients
                        receiving sedation are unable to report isoniazid or linezolid-induced neuropathies nor
                        aminoglycoside- induced otovestibular toxicity</p></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>Rapidly progressive and often fatal. High plasma levels needed to achieve adequate CNS penetration.
                        High index of suspicion necessary; microbiological diagnostic tests have low yield.</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>1-IV rifampin ≥ 10 mg/kg daily+<br>
                        2-PO or IV<sup>2</sup> 2 isoniazid UD+<br>
                        3-PO pyrazinamide UD+<br>
                        4-PO ethambutol UD (adults) or
                        PO ethionamide (children)
                        <p>Consider adding IV levofloxacin or moxifloxacin UD in lieu of ethambutol, especially if there is concern for isoniazid-resistant TB.</p></td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>Rifampin has poor CNS penetration but is an essential drug for meningeal TB treatment. Isoniazid,
                        pyrazinamide, levofloxacin, and moxifloxacin have excellent CNS penetration.
                        <p>Ethambutol has poor CNS penetration. Early use of fluoroquinolones has been associated with
                            improved outcomes among patients with isoniazid-resistant meningeal TB</p></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>Increased risk for pyrazinamide-induced hepatotoxicity</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>Can consider rifampin, isoniazid, and ethambutol without pyrazinamide when drug-susceptibility is
                        known and/or patient has low burden of disease</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>3-drug regimens may increase risk of failure or acquired drug-resistance.</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>Disseminated TB is associated with gut edema which decreases po medication bioavailability</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>Standard 4-drug regimen Consider increasing po Rifampin dose (15 to 20 mg/kg daily, minimum 600 mg)
                        Consider IV rifampin and IV isoniazid 1 for inpatients.</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>Consider obtaining TB drug levels in ensure po dosing achieves at least minimum levels</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>Tube feeds may decrease TB drug bioavailability</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>No change in standard TB regimen</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>Hold tube feeds ≤2 hours prior and ≥1 hour after TB drug intake. Longer intervals are needed if
                        quinolone- containing regimens are given with divalent-cationcontainingtubefeeds</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>Consider limiting number of hepatotoxic drugs for patients with baseline ALT>3x UNL and/or advanced
                        liver disease.
                        Order of hepatotoxicity: PZA>INH>RIF</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>1-RIF/INH/EMB +/- FQN 2-RIF/EMB/FQN +/- LZD or AG 3-EMB/FQN +/- LZD or AG</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>Consider baseline liver enzyme elevation could be due to hepatic TB
                        <p>3-drug regimens may increase risk of failure or acquired drug-resistance.</p></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <td>TB drug-induced hepatotoxicity
                        Stop TB drugs if ALT>3x UNL and patient symptomatic or ALT >5x UNL regardless of symptoms</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Regimen</th>
                    <td>Sequential re-introduction of TB drugs once ALT <2x UNL.
                        (1) Rifamycin x 5-7 days
                        (2) Isoniazid x 5-7 days
                        (3) Ethambutol x 5-7 days
                        (4) Need and choice of 4th agent depends on burden of disease and drug-susceptibility pattern.</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Comments</th>
                    <td>Pyrazinamide is often the culprit and effective regimens can be designed without this drug.
                        Rifamycins are the drugs most important for sterilizing activity (i.e., cure) in TB treatment.
                        Consider adding a 4th drug if patient has high burden of disease.</td>
                </tr>
                </tbody>
            </table>
        </div>

        <p>Abbreviations: UD, usual dose; UNL, upper normal limit.</p>
        <p>TABLE 15 NOTES</p>
        <P>1-Some of these recommendations differ or are not addressed by 2016 ATS/CDC/IDSA drug-susceptible TB
            guidelines. Drug-susceptibility testing for second-line drugs should be requested if these agents are
            used.</P>
        <P>2-Limited availability</P>
        <p>3-Associated with peripheral neuropathy. Add B6 ≥50 mg/daily</p>
        <p>4-Associated with irreversible peripheral and optic neuritis. Add B6 ≥ 50 mg/daily</p>
        <p>5-Associated with otovestibular toxicity</p>
        <p>6-These recommendations are meant for patients with known drug-susceptible TB or at low risk for drug-
            resistant TB</p>
    </div>
</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>
<script>
    // Initialize the first tab as active
    document.addEventListener('DOMContentLoaded', function() {
        const tableContainer = document.getElementById('table_15_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated');
        activateTab(tableContainer, 0);
    });
</script>
</html>
